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Abstract 
Purpose: To evaluate the role of signal transducer and activator of transcription 3 (STAT3) and mucin 
1(MUC1) in non-small cell lung carcinoma (NSCLC) and the use of their inhibitors to reduce 
chemoresistance.  
Methods: Cisplatin or vinblastine was provided either with or without STAT3 inhibitor and evaluated for 
chemoresistance in NSCLC cells and a xenograft mice tumor model. Immunohistochemistry and 
Kaplan-Meier method of survival analysis were used to determine chemoresistance trends in patients. 
STAT3 inhibitor treatment, RNAi or ectopic overexpression of STAT3 or MUC1 in NSCLC cells were 
used to determine their inter-molecular relation and for modulating stemness-related genes.  
Results: A major subset of chemoresistance patients exhibited a combined aberration of both STAT3 
and MUC1 and exhibited a significantly reduced median overall survival (p = 0.008). Subsequent in vitro 
experiments in NSCLC cells showed that STAT3 levels modulate  MUC1 expression (p < 0.01) and 
increase stemness gene expressions such as AKT (3-fold), OCT4 (4-fold), SOX2 (2-fold) and CXCR4 
levels (2 -fold). In addition, co-treatment of STAT3 inhibitor with cisplatin or vinblastine enhanced drug 
efficiency in viability and invasion assays (p < 0.01) and in a xenograft mouse model (p < 0.05). 
Conclusion: STAT3 inhibitor co-treatment with chemotherapy drugs increases drug efficacy and 
reduced tumor growth, and therefore, may improve outcomes in patients on NSCLC chemotherapies.    
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Non-small cell lung carcinoma (NSCLC) 
accounts for > 80 % of all lung cancers including 
lung adenocarcinoma and squamous cell 
carcinoma [1-4]. Treatment options such as 
surgical resection, radiotherapy, and 
chemotherapy are widely used for disease 
management [4-7]. However, tumor resistance to 
these options is a major problem and often leads 
to tumor recurrence and eventually failure of all 
treatment options. Stemness in cancer cell 
populations is widely implicated for facilitating the 
chemoresistance. Stemness in cancer cell 
population is widely implicated for facilitating the 
chemoresistance [7-10]. Developing tailor-made 
chemotherapeutic options based on cancer sub-
types and the underlying facilitating mechanism 
for the chemoresistance has been proposed as 
an alternate strategy to improve outcomes [11]. 
In particular, chemotherapy options for lung 
cancers could be improved by synergistically 
treating with drugs that block tumor survival 
pathways.  
Han et al 
Trop J Pharm Res, July 2017; 16(7): 1514  
 
Multiple studies have shown that STAT proteins 
particularly, STAT3 is abnormally activated in a 
wide variety of cancer type including NSCLC, 
and targeting them could provide therapeutic 
options [12-17]. Similarly, MUC1 protein, which is 
modulated by STAT3 levels, is also indicated to 
facilitate for tumor survival and progression 
[18,19]. Also, as both STAT3 and MUC1 are 
aberrantly associated with multiple cancer types 
including NSCLC, it is intriguing to hypothesize 
that both of them might play a critical role in lung 
cancer progression, and targeting this axis could 
aid in the chemotherapy efficiency.  
 
In this study, we have investigated the 
relationship between STAT3 and MUC1 in the 
context of NSCLC cell survival and evaluated its 







Resected tissue samples were collected from a 
total of 58 patients with NSCLC. All patients 
samples were collected from the Binzhou City 
Central Hospital and selected based on the 
following criteria: (1) underwent complete 
resection of lung cancer with lymph node 
dissection followed by (2) chemotherapy as the 
only treatment used. The study group composed 
28 men and 24 women, and all ranging from the 
age group of 42 - 68 years. The resected 
samples were evaluated for STAT3 and MUC1 
overexpression. All samples were collected after 
prior ethical approval from the hospital review 
board at Binzhou City Central Hospital, Binzhou, 
Shandong (protocol approval no. BZLC2015) ) 
and used as per the revised guidelines of 
International Ethical Guidelines for Biomedical 
Research involving Human Subjects, Council for 
International Organizations of Medical Sciences 
(CIOMS) and World Health Organisation (WHO), 
1993 (update 2002) [20].  
 
Cell culture  
 
H441 human NSCLC cells were purchased from 
American Type Culture Collections (ATTC, MD) 
and maintained in high glucose DMEM medium 
supplemented with 2 mM L-glutamine and 10 % 
fetal bovine serum. Cells were maintained in 37 




C188-9 (STAT3 inhibitor) (Sigma, USA) were 
prepared as 20 mM stock in DMSO and stored at 
-20 ºC. Cells were treated with C188-9 at a final 
concentration of 3 µM and evaluated for changes 
as indicated. Cisplatin and vinblastine (Sigma, 
USA) were prepared as 100 mM stocks in DMSO 
and treated as indicated.  
 
RNAi and overexpression experiments 
 
siRNA targeting for human STAT3 or MUC1 
were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Cells were transfected with 
respective siRNA and evaluated for changes in 
mRNA and protein after 72 h. For overexpression 
experiments, pCMV6–STAT3 or MUC1 (Origene, 
MD) constructs were transfected and analyzed 





Total RNA was isolated from 72 h post-
transfected cultures and reverse transcribed as 
described previously [21]. PCR was performed 
with a 7500 Applied Biosystem instrument using 
TaqMan probes with universal PCR Master Mix 
(Life Technologies, USA). The following prob-es 
were used: TaqMan: MUC1: Hs00904314_g1; 
STAT3: Hs01047580_mL; glyceraldehyde 3-
phosphate dehydrogenase (GAPDH): 
Hs02758991_g1; (Applied Biosystems, USA). 
Untreated samples were used as references to 




The cell lysates were separated on a 4-20 % gel 
under reducing conditions, transferred to a PVDF 
membrane (Bio-Rad, USA), and blotted using 
specific antibodies. The membranes were 
blocked with 3 % milk and probed with primary 
antibodies. The primary antibodies and the 
dilutions were used as follows: rabbit STAT3 
(79D7, Cell Signaling Technology, USA, 1:1000), 
rabbit MUC1 (D908K, Cell Signaling Technology, 
USA, 1:1000), rabbit OCT4 (P0056, Sigma, USA 
1:500), rabbit CXCR (UMB2, Abcam USA, 
1:500), rabbit SOX2 (D6D9, Cell Signaling 
Technology, USA, 1:1000), rabbit AKT (C67E7, 
Cell Signaling Technology, USA, 1:1000) and 
mouse Actin (8H10D10 Cell Signaling 
Technology, USA, 1:2000). Following the primary 
antibody incubation, the membranes were then a 
washed and incubated with respective secondary 
antibodies conjugated with horseradish 
peroxidase (HRP) and developed using a 
chemiluminescence substrate (Super Signal 
West Dura, Pierce Biotechnology, USA).  
Densitometry analysis was used to determine the 
relative fold change in protein levels. 
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Resected tissue samples were paraffin 
embedded and processed as previously 
described [21]. Also, the sections were de-
paraffinized, antigen-retrieved and probed for 
STAT3 or MUC1 proteins. Expression levels from 
the non-cancerous region sections were 
compared as controls.  Two pathologists who 
were blinded to the clinical outcome 
independently evaluated immunostaining scores 
and samples were grouped either or and 
negative for overexpression of STAT3 or MUC1 
based on staining intensity on different samples. 
 
Cell viability and invasion assay 
 
Cell viability after treatments was measured 
using calorimetrically 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(Sigma, USA). Furthermore, control or STAT3 
knockdown (post 72 h siRNA transfected) cells 
(1 × 104 per well) were seeded in a 96-well plate 
and treated with 10 µM cisplatin or vinblastine. 
After 16 h, 50 µL of MTT reagent (1 mg/mL) was 
added and incubated for 1 h.  Absorbance values 
were measured at 570 nm using a microplate 
reader and percent changes in viability for 
different groups were calculated. These time 
incubations were used to allow probing for 
changes in drug response within the time-span of 
siRNA induced STAT3 reduction is retained.  For 
STAT3 inhibitor based experiments, STAT3 
inhibitor and drugs at 10 µM or 30 µM were co-
treated.  
 
For the migration assay, cells were seeded to 
upper Transwell chambers (Costar) at 1 × 104 
cells/well and plated with or without drugs (10 
µM). For invasion assays, cells were plated on 
the matrigel-coated surface (BD biosciences) in a 
transwell chamber and plated with or without 
drugs (10 µM). After overnight incubation, cells 
that have invaded and migrated to the other side 
of the matrix were fixed and stained with a 
solution of 0.5 % crystal violet prepared in 20 % 
ethanol. Cells were counted in 5 fields under an 
inverted microscope at ×200 magnification. 
 
Xenograft animal model 
 
All animal experiments were performed with prior 
approval from Institute’s Animal Care Committee 
at Binzhou City Central Hospital, Binzhou, 
Shandong. Housing and followed the guidelines 
in compliance with the Animals (Scientific 
Procedures) Act, 1986 (UK) (amended 2013) and 
reported as per the ARRIVE Guidelines for 
reporting animal research [22].  
 
To induce tumors in mice, 1 × 105 H441 cells 
were mixed with matrigel and subcutaneously 
inoculated into the flanks of six weeks old 
BALB/c/nude mice (n = 5 per group).  Drugs 
were administered as i.v injection at a 
concentration of 3 mg/kg, once a week. The 
STAT3 inhibitor was provided along with the drug 
injections at a concentration of 3 µM/kg. The 
tumor size was measured using calipers in five-
day intervals. Five weeks after the inoculation, 
the endpoint analysis for MUC1 mRNA analysis 




Kaplan-Meier method of analysis was used to 
calculate the overall survival times in patients. 
Patients (n = 3) with the lack of survival time info 
or mortality due to other causes were censored. 
Of them, 2 were STAT3 positive patients and 1 
was MUC1 positive patient. Chi-square test was 
used to find the correlation between the gene 
expression profile and tumor outcome. For other 
statistical analysis, one-way analysis of variance 
(ANOVA) was used. Statistical significance was 
set at p < 0.05. All calculations were made using 




STAT3 and MUC1 levels in chemoresistant 
NSCLC   
 
STAT3 and MUC1 expressions were evaluated 
by separating the patient groups based on their 
tumor types (Table 1). Our results showed that 
both squamous cell carcinoma and 
adenocarcinoma types exhibited high levels of 
STAT3 or MUC1 expression (Figure 1B), which 
indicate a role for these proteins in tumor 
progression [13,23]. In addition, we noted a 
considerable population of samples showing a 
combined overexpression of both STAT3 and 
MUC1 (Table 1 and Figure 1B).  Statistical 
analysis through Chi-square test yielded a 
statistically significant association for the over-
expression of STAT3 and MUC1 with tumor 
characteristics (p = 0.027). Further analysis 
using Kaplan-Meier method was made to 
determine if there are differences in the overall 
survival (OS) of these patients (Figure 1B). Our 
results showed that median OS for STAT3 and 
MUC1 over-expression patients were 78 and 75 
months respectively, while it is reduced to 46 
months (p < 0.008) in patients with the combined  
Han et al 




Figure 1: STAT3 and MUC1 levels with NSCLC prognosis. (A) Kaplan-Meier survival analysis in different patient 
groups. Patients with both STAT3 and MUC1 positive expression displayed significantly worse outcomes 
compared with other patients (P = 0.008). (B) Representative immunohistochemical staining for STAT3 and 
MUC1 in NSCLC patient samples. Staining from the non-tumor region in patients were shown as controls. * 
represents the bronchial/alveolar regions of the lung. Magnification at 20X. 
 
Table 1: Patient’s count split up based on histology of NSCLC and MUC1 and STAT3 staining 
 
Histology STAT3 positive 
MUC1 
positive 
Both STAT3 and 
MUC1positive 
Both STAT3 and 
MUC1 negative 
Squamous Cell Carcinoma 4 5 16 4 
Adeno Carcinoma 5 6 15 2 
Others 0 0 1 0 
Total   9 11 32 6 
 
overexpression of STAT3 and MUC1. The 
median OS for patients with no expressions of 
both proteins was undefined.  
 
Among the 58 NSCLC patients, ~55 % had both 
STAT3 and MUC1 high expression, while 15% 
had STAT3 and 18 % had MUCl high expression 
levels respectively. Chi-square test was 
performed and statistically, significant correlation 
was identified between STAT3 and MUC1 
expressions and tumor pathology type (p = 
0.023). 
 
STAT3 levels regulate MUC1 expression in 
cells 
 
To understand the relationship between STAT3 
and MUC1 in cells, NSCLC cells (H441) that are 
known to express both the proteins were 
evaluated for changes in either of their gene 
knockdown conditions. We observed a significant 
decrease in the MUC1 mRNA (75 %) and protein 
levels (> 3 fold) (Figure 2), upon STAT3 
knockdown. Treatments with STAT3 inhibitors 
were also able to recapitulate similar reduction in 
MUC1 mRNA (65 % reduction) and protein (> 3 
fold), indicating that STAT3 activity could 
regulate the MUC1 expression in cells. In 
contrast, MUC1 knockdown showed a very slight 
reduction in STAT3 levels (25 % mRNA 
reduction), suggesting that STAT3 might act 




STAT3 and MUC1 regulate stemness in cells 
 
The stemness and survival related signaling 
pathways were investigated upon STAT3 or 
MUC1 knockdown in cells by evaluating for 
PI3K/AKT, OCT4, c-Src, CXCR4, and SOX2.  
The results showed a decrease in AKT (~ 3 fold), 
OCT4 (> 4 fold), SOX2 (> 2 fold) and CXCR4 
levels (2 fold) in STAT3 knockdown cells, while 
Src expression remains unchanged (Src data not 
shown).  In contrast, MUC1 knockdown showed 
minimal changes in OCT4, SOX2, and CXCR4, 
and unchanged for Src (Figure 3). Over-
expression of STAT3 data also showed a 
reversal in the expression patterns of these 
proteins while it remained unchanged with MUC1 
overexpression. 
 
STAT3 inhibition sensitizes cells to 
chemotherapeutic agents 
 
It was observed that STAT3 knockdown and drug 
treatments significantly decreased the number of 
viable cells (20 % change in drug alone and 50 
% change in STAT3 knockdown and drug group; 
p < 0.05). Similar results were observed upon 
STAT3 inhibitor treatments as well (Figure 4). 
 
Subsequent analysis with STAT3 inhibitor in 
migration and invasion assays also showed that 
STAT3 inhibitor significantly enhanced drug 
response in inhibiting both the migration and 
invasion capacity of the cells. (40 % change in 
drug alone groups and 70 % change in drug and 
inhibitor groups; p < 0.01) (Figure 4).
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Figure 2: STAT3 modulates MUC1 expression in cells. (A) MUC1 mRNA changes upon STAT3 siRNA or 
inhibitor treatment and STAT3 mRNA changes upon MUC1 siRNA treatments. (B) Protein changes in treatments 
as described in (A).  STAT3 siRNA or inhibitor treatments showed a significant reduction in MUC1 mRNA and 
protein, while a less apparent reduction was seen in STAT3 mRNA and protein due to MUC1 siRNA treatments. 




Figure 3: STAT3 and MUC1 regulate stemness in cells (A & B) Immunoblot analysis of stemness-related genes 
OCT4, CXCR SOX2, AKT upon knockdown or overexpression of STAT3 or MUC1. (A) Knockdown of STAT3 and 
MUC1. STAT3 knockdown showed the reduction in OCT4, CXCR, SOX2. (B) Overexpression of STAT3 and 
MUC1. STAT3 overexpression increased OCT4, CXCR, SOX2 levels 
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Figure 4: STAT3 inhibition sensitizes cells to chemotherapeutic drugs. (A & B) Cell viability evaluation upon 
STAT3 knockdown/inhibitor treatments and with drug treatments. Reduced STAT3 levels by knockdown or 
STAT3 inhibitor treatment alone had no effect on cell viability. Chemotherapeutic drugs cisplatin and vinblastine 
reduced the cell viability, which is enhanced manifold with STAT3 knockdown or STAT3 inhibitor co-treatment (* 
p < 0.01; ** p < 0.05). (C&D) Cell Migration and Invasion changes in STAT3 inhibitor co-treatment with drugs . (C) 
Cell Migration changes. Numerical value represents the average number of migrated cells. (D) Invasion Assay.  
Chemotherapeutic drugs reduce the cell migration and invasion, which is further enhanced manifold with STAT3 
inhibitor co-treatment. (* p < 0.05; ** p < 0.01). STAT3 inhibitor treatment alone did not have any effect on cell 
migration and invasion 
 
STAT3 inhibitor reduces tumor growth in 
mice by modulating MUC1 expression. 
 
We evaluated the efficacy of STAT3 inhibition 
and chemotherapy drug treatments in xenograft 
mouse models. As shown in figure 5A, we 
observed an enhanced reduction (> 2 fold 
change  
 
STAT3 inhibitor co-treatment with drugs 
enhances tumor growth reduction in mice  
 
The results showed that STAT3 inhibitor co-
treated mice exhibited an enhanced reduction in 
tumor volume compared to drug alone treated 
mice (> 2 fold change from day 25; drug alone vs 
STAT3 inhibitor and drugs, p < 0.05) (Figure 5A). 
In addition, a significant decrease in MUC1 
mRNA in STAT3 inhibitor and drug-treated tumor 
tissues (> 30 % reduction in all STAT3 inhibitor-
treated groups; p < 0.05) (Figure 5B) were 
observed, while no changes in MUC1 mRNA 
were observed in drug alone treated mice. 
Together, these data indicate that STAT3 
inhibition modulates MUC1 expression but not 
sufficient to induce tumor reduction (Figure 5), 
however, with the drugs it chemo-sensitizes the 




A wide range of mechanisms is proposed for 
inappropriate STAT3 and MUC1 activation in 
cancer [24-26]. This increased knowledge of 
signaling pathways about tumor mechanisms 
could be translated into therapeutic strategies 
with less toxicity than current treatments.  In this 
study, we investigated whether STAT3 and 
MUC1 combined overexpression are correlating 
with NSCLC prognosis. Our results showed an 
association of combined elevated expression of 
STAT3 and MUC1 in cancer patient samples with 
poor chemotherapy response (median overall  
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Figure 5: STAT3 inhibitor reduces tumor growth in mice by modulating MUC1 expression. (A) Change in tumor 
volume with different treatments and at different time points. STAT3 inhibitor treatments combined with cisplatin 
or vinblastine showed the maximum reduction in tumor growth (* p < 0.05) from Day 25.  (B) MUC1 expression in 
tumor samples upon different treatments for Day 25. STAT3 inhibitor treatment and STAT3 inhibitor combined 
with cisplatin or vinblastine treatments showed a significant reduction from control (*p < 0.05), while no significant 
difference was seen between them 
 
survival). Furthermore,   the relationship between 
STAT3 and MUC1 were investigated in NSCLC 
cells and explored the potential to aid in 
chemotherapy drug treatments. Following in vitro 
and in vivo analyses, we concluded that STAT3 
levels regulate MUC1 expression and reducing 
their activity could sensitize the cancer cells to 
chemotherapy drugs. 
 
Our results demonstrated that STAT3 protein is 
constitutively over-expressed in NSCLC, and 
could contribute to the regulation of MUC1 
mRNA and protein levels. Earlier reports have 
also indicated the cross-talk of these proteins 
and have implicated for their functions to 
promote tumor cell survival [17]. However, the 
results from - STAT3 and MUC1 knockdown 
experiments it is evident that - that STAT3 acts at 
the upstream signaling level and regulate the 
MUC1 expression. Although other signals such a 
PI3K/AKT are thought to affect the MUC1 
protein, given that STAT response element is 
present in the promoter region of MUC1 gene, it 
is likely that STAT3 contribution would be critical 
to MUC1 expression.  
 
Multiple remarkable studies have shown that 
stemness in cancer cells contribute to the poor 
response of chemotherapy [27-29]. Recent 
reports have shown that MUC1 plays a critical 
role in regulating de-differentiation, and 
stemness in NSCLC, and in accordance with 
those observations, we have also observed that 
the MUC1 overexpression could increase the 
expression levels of OCT4, SOX2, and CXCR4 
to some extent. However, the results also 
revealed that STAT3 could have a more 
prominent effect on these proteins; thereby 
suggesting that STAT3 mediated regulation of 
stemness could be beyond MUC1 involvement. 
Given that STAT3 mediates MUC1 regulation in 
NSCLC, these changes in the stemness-related 
protein expressions suggests that MUC1 could 
possibly act as a mediator of STAT3 either 
independently or in coordination with other 
proteins in this pathway and confer stemness to 
NSCLC.  
 
Previous studies have shown that sensitizing 
cancer cells to chemotherapeutic agents can 
reduce the side effects as well as balance the 
efficacy and toxicity of chemotherapy [30]. 
Molecular pathways driving cancer progression 
or essential for the cancer cell survival could be 
targeted to sensitize the cells for chemotherapy. 
Multiple studies have highlighted the significance 
of MUC1 in cancer progression and are 
particularly associated with aggressiveness of 
tumors. In addition, approaches targeting MUC1 
in lung cancer cells have also shown to sensitize 
the cancer cells to chemotherapy drugs and 
inhibit their growth [18]. Similarly, STAT3 
inhibitors have also been used in the same 
context, to promote the cancer cell death [31].  
Given that both STAT3 and MUC1 proteins have 
been shown to be critical for tumor cell survival 
and in the context of our data showing that 
STAT3 to regulate MUC1 levels, we evaluated 
the efficacy of chemotherapy drug treatments 
with additional STAT3 inhibition. Our results 
demonstrated that STAT3 inhibition sensitizes 
the NSCLC cells for cisplatin and vinblastine 
treatments and showed decreased viability and 
invasion potency.  Following in vivo experiments 
also showed that these synergistic treatments 
significantly decreased tumor growth in mice, 
compared with cisplatin or vinblastine treatments 
alone. More significantly, we have observed that 
this tumor reduction is associated with an MUC1 
reduction, thereby suggesting that strategic 
reduction of STAT3 could significantly enhance 
chemotherapy response.  
Han et al 




Co-overexpression of STAT3 and MUC1 is seen 
in a significant proportion of NSCLC patients with 
poor prognosis. STAT3 regulates MUC1 and 
confers stemness, and targeting them could 
significantly enhance chemotherapy response in 
cells and mice. Overall, the results suggest that 
STAT3 inhibitor co-treatment with chemotherapy 
drugs could cause a synergistic effect in cancer 
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